Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105343 | 0.88 | ALDH1A1 (0.58) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4105035 | 0.85 | ALDH1A1 (0.62) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4112020 | 0.84 | ALDH1A1 (0.70) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4113017 | 0.84 | ALDH1A1 (0.66) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4127631 | 0.83 | ALDH1A1 (0.62) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4105898 | 0.82 | ALDH1A1 (0.64) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4104084 | 0.82 | ALDH1A1 (0.66) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL4118393 | 0.81 | ALDH1A1 (0.68) | EEF2KALDH1A1HTTHPGDTDP1 | |
| SCHEMBL16888396 | 0.81 | EEF2K (1.00) | EEF2KALDH1A1HTTHPGDLMNA | |
| SCHEMBL4106954 | 0.81 | ALDH1A1 (0.62) | EEF2KALDH1A1HTTHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | disclosed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | disclosed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | disclosed |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | BAUSCH+LOMB OPS B.V. (NL) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | HCCS, HAVCR2, HMBS | EEF2K 2523/4885ALDH1A1 3227/4885HTT 4371/4885 |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | HCCS, HAVCR2, HMBS | EEF2K 2523/4885ALDH1A1 3227/4885HTT 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.